We are live on ! Find out more
INBX icon

Inhibrx
INBX

88 hedge funds and large institutions have $149M invested in Inhibrx in 2025 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 22 increasing their positions, 34 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

1% less capital invested

Capital invested by funds: $151M → $149M (-$2.03M)

2.43% less ownership

Funds ownership: 74.52% → 72.09% (-2.4%)

4% less funds holding

Funds holding: 92 → 88 (-4)

29% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 14

35% less repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 34

Holders
88
Holders Change
-4
Holders Change %
-4.35%
% of All Funds
1.16%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
10
Increased
22
Reduced
34
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
WP
Woodline Partners
California
+$3.94M
2
State Street
State Street
Massachusetts
+$414K
3
RAM
Readystate Asset Management
Illinois
+$347K
4
Franklin Resources
Franklin Resources
California
+$287K
5
Millennium Management
Millennium Management
New York
+$264K

Top Sellers

Rank Fund Capital Flow
1
PHS
PFM Health Sciences
California
-$2.52M
2
BlackRock
BlackRock
New York
-$1.34M
3
ACH
ArrowMark Colorado Holdings
Colorado
-$1.34M
4
SC
Slotnik Capital
Texas
-$1.33M
5
PA
Perceptive Advisors
New York
-$1.11M
Name Holding Trade Value Shares
Change 		Change in
Stake
ACH
26
ArrowMark Colorado Holdings
Colorado
$517K -$1.34M -103,476 -74%
M
27
Murchinson
Ontario, Canada
$482K – – –
BC
28
Birchview Capital
Vermont
$458K – – –
Russell Investments Group
29
Russell Investments Group
United Kingdom
$428K +$38.3K +2,963 +11%
BFM
30
Boothbay Fund Management
New York
$403K – – –
Morgan Stanley
31
Morgan Stanley
New York
$397K -$118K -9,092 -25%
Charles Schwab
32
Charles Schwab
California
$397K -$62.9K -4,864 -15%
RAM
33
Readystate Asset Management
Illinois
$383K +$347K +26,834 New
MWA
34
Meridian Wealth Advisors
Texas
$357K – – –
Susquehanna International Group
35
Susquehanna International Group
Pennsylvania
$329K -$385K -29,800 -56%
EWM
36
Empirical Wealth Management
Washington
$322K – – –
Franklin Resources
37
Franklin Resources
California
$316K +$287K +22,170 New
N
38
Nuveen
North Carolina
$303K -$49.2K -3,807 -15%
YCM
39
Yakira Capital Management
Connecticut
$301K -$195K -15,077 -42%
JC
40
JBF Capital
Colorado
$299K – – –
Corient Private Wealth
41
Corient Private Wealth
Florida
$292K – – –
AllianceBernstein
42
AllianceBernstein
Tennessee
$291K +$32.2K +2,490 +14%
Qube Research & Technologies (QRT)
43
Qube Research & Technologies (QRT)
United Kingdom
$284K -$362K -28,021 -58%
HF
44
HRT Financial
New York
$282K +$256K +19,783 New
APCM
45
Arbiter Partners Capital Management
New York
$282K -$108K -8,336 -30%
Jane Street
46
Jane Street
New York
$276K -$89.5K -6,927 -26%
Barclays
47
Barclays
United Kingdom
$245K +$50.2K +3,881 +29%
MAM
48
Mark Asset Management
New York
$243K +$220K +17,000 New
BCM
49
Bridgeway Capital Management
Texas
$235K +$213K +16,500 New
EI
50
Ethic Inc
New York
$227K +$203K +15,739 New
1
2
3 4 5

INBX Hedge Fund Activity: Q2 2025 in Review

88 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Inhibrx (INBX) for Q2 2025, worth a combined $149M — down 1.3% from $151M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of INBX and 10 opened new positions — a net loss of 4 holders — while 34 trimmed existing stakes and 22 added.

The largest buyer was Woodline Partners, adding an estimated $3.94M. The largest seller was PFM Health Sciences, cutting an estimated $2.52M.

  • 88 institutional investors held Inhibrx (INBX) as of Q2 2025, down from 92 in Q1 2025.
  • Funds reported $149M of Inhibrx stock for Q2 2025, down 1.3% quarter-over-quarter.
  • 10 funds opened new Inhibrx positions in Q2 2025 and 14 closed out, a net change of -4 holders.
  • The largest Inhibrx buyer in Q2 2025 was Woodline Partners, an estimated $3.94M added.
  • The largest Inhibrx seller in Q2 2025 was PFM Health Sciences, an estimated $2.52M sold.

Based on aggregated 13F filings for Q2 2025.